Primer reporte de infección natural de Nematodirus filicollis en un ovino del trópico sub-húmedo mexicano

Objective. The aim of the present study is to report for the first time the natural infection of a sheep with Nematodirus filicollis in the sub-humid tropics of Mexico. Materials and methods. Faecal samples were processed to identify and quantify faecal nematode eggs per gram of feces (EPG) using the flotation and modified McMaster techniques. Also, faecal cultures were made using the Corticelli-Lai technique. Results. The ewe showed a mixed infection with Trichuris spp. (100 EPG), Nematodirus (100 EPG) and other strongylida nematodes (1500 EPG). The egg size of Nematodirus spp. was 202±3 µ long and 97±2 µ wide. Larvae of Haemonchus, Trichostrongylus, Oesophagostomum and Nematodirus genera were identified from de faecal cultures. Nematodirus larvae averaged 955±8.0 µ long and 28±0.5 µ wide. Whereas, the average length of the sheath tail was 233.4±41.6 µ. Conclusions. According to the morphological traits of eggs and larvae, it is concluded that the infection of the sheep corresponded to Nematodirus filicollis. It is concluded that N. filicollis is able to survive in the sub-humid tropics of Mexico and for the first time an acquired natural infection of this nematode in a sheep is reported.Objetivo. El presente estudio tiene por objetivo reportar por primera vez el caso de un ovino que adquirió la infección natural con Nematodirus filicollis en condiciones de clima tropical sub-húmedo. Materiales y métodos. Se tomó una muestra de heces que fue procesada para identificar y cuantificar la excreción de huevos de nematodos por gramo de heces (h/gh) mediante las pruebas de Flotación Centrifugada y McMaster. Asimismo, se realizó un cultivo de larvas mediante la prueba de Corticelli-Lai. Resultados. El ovino presentó una nematodiasis mixta por Trichuris spp. (100 h/gh), Nematodirus spp. (100 h/gh) y otros nematodos del orden strongylida (1500 h/gh). El tamaño de los huevos del Nematodirus fue de 202±3 µ de largo y 97±2 µ de ancho. En el cultivo de larvas se identificaron los géneros Haemonchus, Trichostrongylus, Oesophagostomum y Nematodirus. La longitud promedio de las larvas de Nematodirus fue de 955±8.0 µ y ancho de 28±0.5 µ, mientras que la longitud promedio de la cola de la vaina fue de 233.4±41.6 µ. Conclusiones. Con base en las dimensiones de las larvas y sus características morfológicas se reporta que la infección del ovino fue por Nematodirus filicollis. Se concluye que N. filicollis es capaz de sobrevivir en las condiciones del clima tropical sub-húmedo en México y se reporta por primera vez el caso de un ovino que adquirió la infección natural con este nematodo

Zoonosis, cambio climático y sociedad

La sociedad contemporánea se enfrenta a uno de los retos más grandes de la historia humana, el calentamiento global, mismo que acarrea enormes consecuencias, tales como los disturbios climáticos, así como los patrones de las enfermedades de origen animal transmisibles al hombre. Precisamente ante este escenario las instituciones educativas de nivel superior deben dar cumplimiento a su responsabilidad y ser las generadoras de alternativas de solución mediante el trabajo especializado de investigación; y para ello, la pesquisa científica es la mejor de las alternativas a nuestro alcance para comprender y encarar estos desafíos.Universidad Autónoma del Estado de México y Ediciones y Gráficos Eón, S.A. de C.V

Rhipicephalus(Boophilus) microplus resistant to acaricides and ivermectin in cattle farms of Mexico

Ticks and the diseases they transmit cause great economic losses to livestock in tropical countries. Non-chemical control alternatives include the use of resistant cattle breeds, biological control and vaccines. However, the most widely used method is the application of different chemical classes of acaricides and macrocyclic lactones. Populations of the cattle tick, Rhipicephalus (Boophilus) microplus, resistant to organophosphates (OP), synthetic pyrethroids (SP), amitraz and fipronil have been reported in Mexico. Macrocyclic lactones are the most sold antiparasitic drug in the Mexican veterinary market. Ivermectin-resistant populations of R. (B.) microplus have been reported in Brazil, Uruguay and especially in Mexico (Veracruz and Yucatan). Although ivermectin resistance levels in R. (B.) microplus from Mexico were generally low in most cases, some field populations of R. (B.) microplus exhibited high levels of ivermectin resistance. The CHPAT population showed a resistance ratio of 10.23 and 79.6 at lethal concentration of 50% and 99%, respectively. Many field populations of R. (B.) microplus are resistant to multiple classes of antiparasitic drugs, including organophosphates (chlorpyrifos, coumaphos and diazinon), pyrethroids (flumethrin, deltamethrin and cypermethrin), amitraz and ivermectin. This paper reports the current status of the resistance of R. (B.) microplus to acaricides, especially ivermectin, in Mexican cattle

Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI) : a phase 3, placebo-controlled, randomised trial

Background: Patients with stable coronary artery disease and diabetes with previous percutaneous coronary intervention (PCI), particularly those with previous stenting, are at high risk of ischaemic events. These patients are generally treated with aspirin. In this trial, we aimed to investigate if these patients would benefit from treatment with aspirin plus ticagrelor. Methods: The Effect of Ticagrelor on Health Outcomes in diabEtes Mellitus patients Intervention Study (THEMIS) was a phase 3 randomised, double-blinded, placebo-controlled trial, done in 1315 sites in 42 countries. Patients were eligible if 50 years or older, with type 2 diabetes, receiving anti-hyperglycaemic drugs for at least 6 months, with stable coronary artery disease, and one of three other mutually non-exclusive criteria: a history of previous PCI or of coronary artery bypass grafting, or documentation of angiographic stenosis of 50% or more in at least one coronary artery. Eligible patients were randomly assigned (1:1) to either ticagrelor or placebo, by use of an interactive voice-response or web-response system. The THEMIS-PCI trial comprised a prespecified subgroup of patients with previous PCI. The primary efficacy outcome was a composite of cardiovascular death, myocardial infarction, or stroke (measured in the intention-to-treat population). Findings: Between Feb 17, 2014, and May 24, 2016, 11 154 patients (58% of the overall THEMIS trial) with a history of previous PCI were enrolled in the THEMIS-PCI trial. Median follow-up was 3·3 years (IQR 2·8–3·8). In the previous PCI group, fewer patients receiving ticagrelor had a primary efficacy outcome event than in the placebo group (404 [7·3%] of 5558 vs 480 [8·6%] of 5596; HR 0·85 [95% CI 0·74–0·97], p=0·013). The same effect was not observed in patients without PCI (p=0·76, p interaction=0·16). The proportion of patients with cardiovascular death was similar in both treatment groups (174 [3·1%] with ticagrelor vs 183 (3·3%) with placebo; HR 0·96 [95% CI 0·78–1·18], p=0·68), as well as all-cause death (282 [5·1%] vs 323 [5·8%]; 0·88 [0·75–1·03], p=0·11). TIMI major bleeding occurred in 111 (2·0%) of 5536 patients receiving ticagrelor and 62 (1·1%) of 5564 patients receiving placebo (HR 2·03 [95% CI 1·48–2·76], p<0·0001), and fatal bleeding in 6 (0·1%) of 5536 patients with ticagrelor and 6 (0·1%) of 5564 with placebo (1·13 [0·36–3·50], p=0·83). Intracranial haemorrhage occurred in 33 (0·6%) and 31 (0·6%) patients (1·21 [0·74–1·97], p=0·45). Ticagrelor improved net clinical benefit: 519/5558 (9·3%) versus 617/5596 (11·0%), HR=0·85, 95% CI 0·75–0·95, p=0·005, in contrast to patients without PCI where it did not, p interaction=0·012. Benefit was present irrespective of time from most recent PCI. Interpretation: In patients with diabetes, stable coronary artery disease, and previous PCI, ticagrelor added to aspirin reduced cardiovascular death, myocardial infarction, and stroke, although with increased major bleeding. In that large, easily identified population, ticagrelor provided a favourable net clinical benefit (more than in patients without history of PCI). This effect shows that long-term therapy with ticagrelor in addition to aspirin should be considered in patients with diabetes and a history of PCI who have tolerated antiplatelet therapy, have high ischaemic risk, and low bleeding risk